12 Stocks with Heavy Insider Buying in 2025

3. Biohaven Ltd. (NYSE:BHVN)

Number of Hedge Fund Holders: 41

Biohaven Ltd. (NYSE:BHVN) is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neurological and neuropsychiatric diseases. The company’s portfolio includes therapies targeting conditions such as spinocerebellar ataxia, amyotrophic lateral sclerosis, and multiple system atrophy. BHVN leverages proprietary technology platforms to advance its drug development pipeline. Following its spin-off in October 2022, BHVN has been actively pursuing clinical studies and collaborations to bring novel therapies to patients with unmet medical needs.

Biohaven Ltd. (NYSE:BHVN) reported positive topline results in their 3-year study of troriluzole for treating spinocerebellar ataxia (SCA), demonstrating a 50% slowing in disease progression on the study’s primary outcome measure. The treatment resulted in a significant 1.5-year treatment gain over the course of the 3-year study, with efficacy demonstrated across 9 prespecified outcome measures while maintaining a safe and well-tolerated profile. Based on these results, the company plans to submit a new drug application to the FDA for troriluzole in treating all SCA genotypes by the end of the year, with expectations for an accelerated review based on previously granted orphan drug and fast-track designations.

The commercial opportunity for Biohaven Ltd. (NYSE:BHVN) is substantial, with approximately 15,000 people affected by SCA in the US and 24,000 in Europe and the UK, representing both a high unmet need and a large commercial market. The company has strong IP protection with NCE composition of matter patent expiration anticipated in 2041 with extensions. The treatment demonstrated remarkable efficacy, showing a 50% to 70% slowing of disease progression over 3 years, reflecting a 1.5- to 2.2-year delay in SCA decline across different analysis cohorts. Additionally, troriluzole showed a 53% reduction in relative risk of falls in treated patients, with an even more pronounced 60% reduction in ambulatory patients. The strong opportunities for BHVN are further reinforced by at least two insiders buying more than $500,000 worth of company stock in the last six months.